At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 96 enrolled
Drug / intervention
Herpes Zoster vaccine (GSK1437173A)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
In Brief
A Phase 3 clinical trial evaluating Herpes Zoster vaccine (GSK1437173A) for Herpes Zoster. Completed, enrolled 96 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ). The data collected will be compared with the data from subjects without HZ in other HZ/su trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesCanada, Russia
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartJun 2013
Primary CompletionFeb 2014
Study CompletionNov 2014
TodayJul 2026
First PostedApr 10, 2013
Enrollment StartJun 10, 2013
Primary CompletionFeb 10, 2014
Study CompletionNov 25, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.2 years ago
Interventions
Herpes Zoster vaccine (GSK1437173A)biological
2 doses administered intramuscularly in deltoid region of non-dominant arm.